Anti-DLL4 Antibody (Navicixizumab)
Catalog No.
F1540
Anti-DLL4 Antibody (Navicixizumab)
Featured Products
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can be used in combination with paclitaxel for cancer research. Navicixizumab can be used in the study of ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.17 kDa
Dry ice
1638338-43-8
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
OMP-305B83
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9NR61
Human
Unconjugated
Monoclonal
Protein A
IgG2SA
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human VEGF165 His at 2 ug/mL can bind Anti-DLL4 Antibody (Navicixizumab)
DLL4
Please avoid freeze-thaw cycles.